Scaffolded Multivalent Blockers for Nucleic Acid Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing non-specific interactions of nucleic acids suffer from limitations, particularly due to the strong negative charge of nucleic acids leading to electrostatic affinity with positively charged molecules, resulting in undesired sequestration, off-target signals, and reduced yield in therapeutic and diagnostic applications.
Innovation Solution
Development of multivalent blockers comprising at least two negatively charged polymers linked to a scaffold, which bind to positively charged compounds to block non-specific interactions with nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional blocking agents (single-stranded or double-stranded nucleic acids) are used to prevent non-specific interactions, then the negative charge of nucleic acids provides electrostatic repulsion, but the blocking efficiency is insufficient and non-specific binding still occurs
Solution Approach 1:
The patent uses composite materials by combining multiple negatively charged polymer chains with a scaffold structure to create multivalent blockers. This composite approach enhances blocking efficiency through cooperative electrostatic interactions while maintaining structural organization that prevents non-specific binding.
Solution Approach 2:
The blocker is segmented into multiple identical or similar negatively charged polymer units attached to a scaffold. This segmentation allows each unit to independently interact with positively charged molecules, providing redundant blocking capability and enhanced overall efficiency.
2Reliability
If multivalent blockers with multiple negatively charged polymers are used to enhance blocking efficiency, then non-specific interactions are reduced, but the molecular complexity and size of the blocker increase
Solution Approach 1:
The multivalent blocker structure serves multiple functions simultaneously: the scaffold provides structural organization and valency, while the multiple negatively charged polymer chains collectively provide electrostatic repulsion and binding competition. This multi-functionality achieves enhanced blocking efficiency without requiring fundamentally different molecular components.
Solution Approach 2:
The patent merges multiple identical or similar polymer units with a scaffold structure to create a unified multivalent blocker. This combining approach concentrates blocking activity in a single molecular entity, improving efficiency while keeping the design systematic and manageable.
3Measurement precision
If traditional blocking methods are used, then the assay workflow remains simple, but non-specific binding causes background signals and reduces detection sensitivity
Solution Approach 1:
The multivalent blocker acts as an intermediary substance that mediates between the nucleic acid targets and positively charged interfering molecules. By introducing this intermediary, the patent eliminates non-specific binding pathways without requiring fundamental changes to the assay workflow or detection methodology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multivalent blockers effectively reduce non-specific interactions, enhancing the reliability of nucleic acid-based therapies, diagnostics, and sequencing by minimizing off-target effects and maintaining assay specificity.
Implementation Method 1
the strong negative charge of nucleic acids leading to electrostatic affinity with positively charged molecules
Data Source
AI summary
Methods and reagents for blocking non-specific interactions with nucleic acids are disclosed. In particular, the invention relates to multi-valent blockers comprising multiple negatively charged polymers or materials attached to a common scaffold and their use in blocking non-specific interactions with nucleic acids.